Get the Stockscreener App
8.62
3.79%
-0.34
Pre-market:
8.60
-0.02
-0.23%
Ars Pharmaceuticals Inc stock is traded at $8.62, with a volume of 1.45M.
It is down -3.79% in the last 24 hours and down -16.39% over the past month.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
See More
Previous Close:
$8.96
Open:
$8.93
24h Volume:
1.45M
Relative Volume:
0.59
Market Cap:
$851.88M
Revenue:
-
Net Income/Loss:
$-44.84M
P/E Ratio:
-18.34
EPS:
-0.47
Net Cash Flow:
$-44.23M
1W Performance:
-9.83%
1M Performance:
-16.39%
6M Performance:
-40.39%
1Y Performance:
-43.51%
1-Day Range:
$8.3184
$9.005
1-Week Range:
$8.3184
$9.58
52-Week Range:
$8.3184
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Compare SPRY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
8.62 | 885.48M | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Initiated | Roth Capital | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-10-25 | Initiated | Oppenheimer | Outperform |
| Aug-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-12-24 | Reiterated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | Raymond James | Outperform |
| Mar-05-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-20-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
View All
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
105,000 Shares in ARS Pharmaceuticals, Inc. $SPRY Bought by Hussman Strategic Advisors Inc. - MarketBeat
How ARS Pharmaceuticals Inc. stock trades during market volatilityTreasury Yields & Real-Time Volume Triggers - newser.com
Can ARS Pharmaceuticals Inc. hit a new high this monthJuly 2025 Fed Impact & Free Community Supported Trade Ideas - newser.com
Why ARS Pharmaceuticals Inc. stock could see breakout soonEarnings Overview Summary & Capital Protection Trade Alerts - newser.com
How ARS Pharmaceuticals Inc. stock benefits from strong dollarSwing Trade & Safe Investment Capital Preservation Plans - newser.com
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting - The Manila Times
UPDATE -- ARS Pharma to Present Real-World Data on - GlobeNewswire
ARS Pharma (Nasdaq: SPRY) to present real-world neffy data: 1 late-breaking oral, 6 posters - Stock Titan
What drives ARS Pharmaceuticals Inc stock priceFlag and Pennant Patterns & Learn to Think Like a Long-Term Investor - earlytimes.in
Why ARS Pharmaceuticals Inc. stock could rally in 20252025 Geopolitical Influence & Consistent Profit Trade Alerts - newser.com
Will ARS Pharmaceuticals Inc. rebound enough to break evenJuly 2025 Short Interest & Expert Curated Trade Setup Alerts - newser.com
ARS Pharmaceuticals (NASDAQ: SPRY) to Host Q3 Results Webcast; Replay for 30 Days - Stock Titan
ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results - Yahoo Finance
ARS Pharma Presents Late-Breaking Oral and Poster Sessions on Real-World Effectiveness of neffy® at ACAAI 2025 Annual Scientific Meeting - Quiver Quantitative
ARS Pharmaceuticals Inc. stock outlook for YEAR2025 Short Interest & Reliable Momentum Entry Alerts - newser.com
ARS Pharma (Nasdaq: SPRY) shares 9 of 10 anaphylaxis cases treated with single-dose neffy - Stock Titan
Custom strategy builders for tracking ARS Pharmaceuticals Inc.Weekly Gains Report & Free Daily Entry Point Trade Alerts - newser.com
Will ARS Pharmaceuticals Inc. stock maintain momentum in 2025Weekly Investment Recap & Technical Pattern Based Signals - newser.com
Trend analysis for ARS Pharmaceuticals Inc. this week2025 Investor Takeaways & Capital Efficiency Focused Strategies - newser.com
Reversal indicators forming on ARS Pharmaceuticals Inc. stockTrade Signal Summary & Expert Verified Stock Movement Alerts - newser.com
Applying chart zones and confluence areas to ARS Pharmaceuticals Inc.Weekly Gains Report & Weekly Market Pulse Alerts - newser.com
Why ARS Pharmaceuticals Inc. stock could outperform in 2025Market Sentiment Report & Short-Term High Return Strategies - newser.com
Is ARS Pharmaceuticals Inc. stock supported by innovation pipelineDividend Hike & Daily Volume Surge Trade Alerts - newser.com
Why ARS Pharmaceuticals Inc. stock is recommended by analystsTrade Volume Summary & Growth Focused Investment Plans - newser.com
ARS Pharmaceuticals Hits New 52-Week Low at $8.59 Amid Financial Struggles - Markets Mojo
Published on: 2025-11-02 04:08:25 - newser.com
Multi factor analysis applied to ARS Pharmaceuticals Inc.Earnings Recap Report & Expert Approved Momentum Trade Ideas - newser.com
How ARS Pharmaceuticals Inc. stock reacts to inflationary pressuresJuly 2025 Outlook & Precise Trade Entry Recommendations - newser.com
Published on: 2025-11-01 01:27:58 - newser.com
ARS Pharmaceuticals (NASDAQ:SPRY) Hits New 52-Week LowWhat's Next? - MarketBeat
How ARS Pharmaceuticals Inc. stock valuations compare to rivalsWeekly Stock Recap & Low Drawdown Investment Ideas - newser.com
Is ARS Pharmaceuticals Inc. a candidate for recovery playWeekly Stock Report & AI Forecasted Entry/Exit Points - newser.com
ARS Pharmaceuticals Hits New 52-Week Low at $8.90 Amid Financial Struggles - Markets Mojo
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):